Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 3
2016 3
2017 4
2018 3
2020 1
2021 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Inhibitor development and mortality in non-severe hemophilia A.
Eckhardt CL, Loomans JI, van Velzen AS, Peters M, Mauser-Bunschoten EP, Schwaab R, Mazzucconi MG, Tagliaferri A, Siegmund B, Reitter-Pfoertner SE, van der Bom JG, Fijnvandraat K; INSIGHT Study Group. Eckhardt CL, et al. Among authors: van velzen as. J Thromb Haemost. 2015 Jul;13(7):1217-25. doi: 10.1111/jth.12990. Epub 2015 Jun 10. J Thromb Haemost. 2015. PMID: 25912309 Free article.
Summary report of the First International Conference on inhibitors in haemophilia A.
Lacroix-Desmazes S, Scott DW, Goudemand J, Van Den Berg M, Makris M, Van Velzen AS, Santagostino E, Lillicrap D, Rosendaal FR, Hilger A, Sauna ZE, Oldenburg J, Mantovani L, Mancuso ME, Kessler C, Hay CRM, Knoebl P, Di Minno G, Hoots K, Bok A, Brooker M, Buoso E, Mannucci PM, Peyvandi F. Lacroix-Desmazes S, et al. Among authors: van velzen as. Blood Transfus. 2017 Oct;15(6):568-576. doi: 10.2450/2016.0252-16. Epub 2016 Nov 25. Blood Transfus. 2017. PMID: 27893354 Free PMC article. No abstract available.
Desmopressin in moderate hemophilia A patients: a treatment worth considering.
Loomans JI, Kruip MJHA, Carcao M, Jackson S, van Velzen AS, Peters M, Santagostino E, Platokouki H, Beckers E, Voorberg J, van der Bom JG, Fijnvandraat K; RISE consortium. Loomans JI, et al. Among authors: van velzen as. Haematologica. 2018 Mar;103(3):550-557. doi: 10.3324/haematol.2017.180059. Epub 2018 Jan 5. Haematologica. 2018. PMID: 29305412 Free PMC article.
Inhibitors in nonsevere haemophilia A: outcome and eradication strategies.
van Velzen AS, Eckhardt CL, Hart DP, Peters M, Rangarajan S, Mancuso ME, Smiers FJ, Khair K, Petrini P, Jiménez-Yuste V, Hay CR, van der Bom JG, Yee TT, Fijnvandraat K; INSIGHT study group. van Velzen AS, et al. Thromb Haemost. 2015 Jul;114(1):46-55. doi: 10.1160/TH14-11-0940. Epub 2015 Apr 16. Thromb Haemost. 2015. PMID: 25879247
Treatment-related risk factors for inhibitor development in non-severe hemophilia A after 50 cumulative exposure days: A case-control study.
Abdi A, Eckhardt CL, van Velzen AS, Vuong C, Coppens M, Castaman G, Hart DP, Hermans C, Laros-van Gorkom B, Leebeek FWG, Mancuso ME, Mazzucconi MG, McRae S, Oldenburg J, Male C, van der Bom JG, Fijnvandraat K, Gouw SC; INSIGHT Study Group. Abdi A, et al. Among authors: van velzen as. J Thromb Haemost. 2021 Sep;19(9):2171-2181. doi: 10.1111/jth.15419. Epub 2021 Jul 19. J Thromb Haemost. 2021. PMID: 34107158 Free PMC article.
15 results